ArticleLancet regional health. Americas2026
The ENGAGE study: a randomized trial optimizing uptake of germline cancer genetic services in childhood cancer survivors.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04455698 (Engaging and Activating Cancer Survivors in Genetic Services Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Engaging and Activating Cancer Survivors in Genetic Services Study
Who cites it
1 citing paper in PubMed.
- Beyond survival: the risk of subsequent primary melanoma in childhood cancer survivors.Journal of the National Cancer Institute · 2026Article
Corrections and comments
- Update of
Authors and funding
18 authors.
Funding
Abstract
Background: Identifying childhood cancer survivors who are already at high risk of subsequent neoplasms and may also have an inherited genetic susceptibility is essential for effective surveillance and prevention. This trial evaluated the effectiveness of remote, centralized telehealth genetic services in increasing service uptake. Methods: Childhood Cancer Survivor Study (CCSS) participants at the St. Jude Research Hospital, who were ≥18 years old and survivors of a CNS tumor, sarcoma, or more than one primary cancer, were recruited for the study. After completing a baseline survey, participants were randomly assigned to one of the two arms: remote telehealth genetic services (via phone or videoconference) or usual care. Uptake of genetic services was obtained through study records and the six-month Status Survey. This trial was registered with ClinicalTrials.gov (NCT04455698), and accrual has closed. Findings: Of the 391 participants recruited, 262 were assigned to remote telehealth services (via phone or videoconference) and 129 to usual care. At six months, 43% (113/262) of participants in remote telehealth services received genetic services compared to 15% (19/129) in the usual care group (OR = 4.4, 95% CI: 2.5-8.0, p < 0.0001). Uptake of genetic counseling (42% vs. 15%, p < 0.0001) and genetic testing (19% vs. 9%, p = 0.020) were higher in remote telehealth services. Factors associated with higher uptake included not having high-deductible health insurance (OR = 1.67, 95% CI: 1.00-2.91, p = 0.049) and lower perceived cost of testing (OR = 1.51, 95% CI: 1.17-1.96, p = 0.0014). Top barriers included experiencing higher levels of depression (OR = 0.91, 95% CI: 0.85-0.98, p = 0.0067) and anxiety (OR = 0.93, 95% CI: 0.87-1.00, p = 0.036). Interpretation: Remote telehealth genetic services improve genetic counseling and testing uptake in childhood cancer. Addressing remaining barriers could maximize their impact and ensure equitable access for childhood cancer survivors and their families. Funding: National Cancer Institute (R01-CA237369, U24-CA55727).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.